![](/img/cover-not-exists.png)
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
Aranda, E., García Alfonso, P., Benavides, M., Sánchez Ruiz, A., Guillén-Ponce, C., Safont, M.J., Alcaide, J., Gómez, A., López, R., Manzano, J.L., Méndez Ureña, M., Sastre, J., Rivera, F., Grávalos,Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2018.06.024
Date:
July, 2018
File:
PDF, 1.52 MB
english, 2018